Fig. 4. BRG1 facilitates tumor growth in vivo.
Five-week-old female NOD-Prkdcscid IL2rgnull (NTG) mice (n = 8/group) were administered 1 × 107 Nalm-6/Sh-BRG1 cells, Nalm-6/Sh-Ctrl cells, RS4:11/LV-BRG1 cells or RS4:11/LV-Vector cells via tail vein injection. A Schematic diagram of injected cells into NTG mice. The survival of diseased mice was monitored. Peripheral blood (PB) was collected weekly from the mice angular vein and labeled with anti-human CD45+ antibody and analyzed by flow cytometry. Proportion of CD45+ cells in human B-ALL cells in the angular vein of Nalm-6 mice (B) and RS4:11 mice (C). After the mice were sacrificed, bone marrow (BM) cells were labelled with anti-human CD45+ and CD19+ antibodies. Flow cytometry was used to assess the engraftment of human cells. D Proportion of human CD45+ and CD19+ cells in the BM of mice in the groups. E, F Survival of mice transplanted with two types of samples (n = 8 per group). Representative gross illustrations of spleen (G) and liver (H) metastases in mice injected with cells. White arrows indicate neoplasm invasiveness. I H&E staining and IHC (BRG1 and Ki67 expression) results of the liver, spleen and femur in the normal, Nalm-6 and RS4:11 groups. The histogram shows the average proportion of BRG1- and Ki67-positive cells (*P < 0.05; **P <0.01).